Denosumab plus romosozumab vs denosumab only was associated with improved bone mineral density among patients with severe postmenopausal osteoporosis.

Biocon Biologics Ltd (“BBL”) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had issued positive ...

Investors are closely monitoring the performance of Indian pharma companies in the March 2025 quarter and their ability to ...

US president Donald Trump's imposition of import tariffs on key goods underscores his 'Made in America' agenda. While ...

Amneal Pharmaceuticals reported first-quarter 2025 adjusted earnings per share of 21 cents, up from 14 cents a year ago.

In osteoporosis, bones lose minerals more than the body can replace them with new ones, leaving them thinner and more brittle. Various factors can increase your risk of developing osteoporosis, with ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523) (NSE: BIOCON), today announced that the Committee for Medicinal Products for H ...

Denosumab biosimilar Vevzuo® is intended for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with ...

Total hip BMD increases were associated with reduced risk for vertebral and all clinical fractures across active control or sequential therapy trials.

Denosumab biosimilars Stoboclo and Osenvelt were approved for osteoporosis and bone loss, demonstrating comparable efficacy and safety to reference drugs. Guselkumab, the first IL-23 inhibitor ...

Pharma major Dr Reddy’s Laboratories Ltd’s consolidated net profit increased 21% in the fourth quarter ended March 31, 2025 ...

Patient had been told she should be on it for the rest of her life to help prevent breast cancer and osteoporosis.